# A Study of Motexafin Gadolinium (MGd) in Combination With Docetaxel and Cisplatin for Treatment of Non-Small Cell Lung Cancer (NSCLC)

> **NCT00102505** · PHASE1 · COMPLETED · sponsor: **Pharmacyclics LLC.** · enrollment: 36 (—)

## Conditions studied

- Non-Small-Cell Lung Carcinoma
- Carcinoma, Bronchogenic

## Interventions

- **DRUG:** Motexafin Gadolinium Injection

## Key facts

- **NCT ID:** NCT00102505
- **Lead sponsor:** Pharmacyclics LLC.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 36 (—)
- **Last updated:** 2009-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00102505

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00102505, "A Study of Motexafin Gadolinium (MGd) in Combination With Docetaxel and Cisplatin for Treatment of Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00102505. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*